GeoVax Appoints Mr. Peter M. Tsolinas to Its Board of Directors

    ATLANTA, Aug. 20 /EMWNews/ -- GeoVax Labs, Inc. (OTC

Bulletin Board: GOVX), an Atlanta based biopharmaceutical company

developing human vaccines for diseases caused by HIV-1 (Human

Immunodeficiency Virus) and other infectious agents, is pleased to announce

the addition of Peter M. Tsolinas as a member of its Board of Directors.

Tsolinas, having supported the Company through private investments, now

joins the Company's Board to further his contribution through his talent

and three decades of business and banking experience.



    Mr. Tsolinas currently serves as Chairman and CEO of TMA Group

Development Corp., a Chicago based real estate, architectural and

development firm. As a real estate developer over the last 30 years,

Tsolinas has built a successful network of companies involved in

architectural, development and construction of commercial, industrial and

institutional facilities. During that time, Tsolinas has participated in

joint ventures and partnerships with Lincoln National Life, Commonwealth

Edison, and ADP Corporation, as well as individual private investors.

Further, Mr. Tsolinas has achieved additional successes through his

personal investments in the real estate and banking sector, where he served

on several bank boards from 1977 through 2006.



    "As a substantial investor in GeoVax, I am honored to join its Board of

Directors to further assist the Company directly," said Tsolinas. "I have

been truly intrigued by Dr. Harriet Robinson's scientific efforts and

dedication to help humanity and I look forward to continue supporting her

and the Company in their quest to cure the HIV/AIDS pandemic."



    Tsolinas continued, "With the exceptional trial data the Company has

demonstrated to date, I envision a very promising future for GeoVax and its

shareholders. I am personally humbled to be an integral part of its success

going forward."



    Robert McNally, GeoVax's President and Chief Executive Officer,

commented, "We are very pleased that Mr. Peter Tsolinas has agreed to join

our Board of Directors. His substantial business experience will enhance

and complement that of our current Board members. Peter has been a faithful

supporter of GeoVax and we welcome his further contributions to our success

through service on our Board."



    Mr. Tsolinas earned a B.A. degree in Architecture with a minor in

Byzantine History from the University of Illinois. He has been a speaker

and panelist at numerous Architectural and Development Conferences and is a

member of the Chicago and National Chapter of The American Institute of

Architects, as well as a corporate member of NCARB and NAIOP. He has been

engaged in several philanthropic projects and currently serves as Chairman

of the Stewardship Committee at St. Nectarios Greek Orthodox Church.

    About GeoVax Labs, Inc.



    GeoVax Labs, Inc. is a biotechnology company, established to develop,

manufacture, license and commercialize human vaccines for diseases caused

by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.

GeoVax's AIDS vaccine technology is the subject of 20 issued or filed

patent applications. GeoVax AIDS vaccines are designed for use in

uninfected people to prevent Acquired Immunodeficiency Disease (AIDS),

caused by the virus known as HIV-1, should the person ever become infected.

GeoVax AIDS vaccines also may be effective as therapeutics, treatment of

people already infected with AIDS virus.



    GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet

Robinson, Senior V.P. of Research and Development, through a collaboration

of colleagues at Emory University's Vaccine Center, the National Institutes

of Health (NIH), The Centers for Disease Control and Prevention (CDC) and

GeoVax.



    GeoVax AIDS vaccines have moved forward in human clinical trials

conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle,

Washington. The HVTN, funded through a cooperative agreement with the

National Institutes of Health (NIH), is the largest worldwide clinical

trials program dedicated to the development and testing of AIDS vaccines.

Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was

funded and supported by NIAID, which provided additional support to GeoVax

AIDS vaccine development program with a $15 million IPCAVD grant awarded in

late 2007.



    Safe Harbor Statement: All statements in this news release, which are

not statements of historical fact, are forward-looking statements. These

statements are based on expectations and assumptions on the date of this

press release and are subject to numerous risks and uncertainties which

could cause actual results to differ materially from those described in the

forward- looking statements. Risks and uncertainties include, but are not

limited to, whether: GeoVax can develop and manufacture these vaccines with

the desired characteristics in a timely manner, GeoVax's vaccines will be

safe for human use, GeoVax's vaccines will effectively prevent AIDS in

humans, vaccines will receive regulatory approvals necessary to be licensed

and marketed, GeoVax raises required capital to complete vaccine

development, there is development of competitive products that may be more

effective or easier to use than GeoVax's products, and other factors over

which GeoVax has no control. GeoVax assumes no obligation to update these

forward-looking statements, and does not intend to do so. Certain matters

discussed in this news release are forward- looking statements involving

certain risks and uncertainties including, without limitation, risks

detailed in the Company's Securities and Exchange Commission filings and

reports.